Pharmalot

Pharmalot

Pharmalittle: Bayer offered funding to influence foreign press group; a key Sanofi exec leaves as changes loom

By Ed Silverman

Pharmalot

Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

By Ed Silverman

Pharmalot

Pharmalittle: Trump and senators push for drug prices in TV ads; Sanofi looks to spin off consumer business

By Ed Silverman

Pharmalot

Pharmalittle: Purdue affiliate in China pushes misleading opioid claims; more generics are approved but not yet available

By Ed Silverman

Pharmalot

FDA is urged to probe a Louisiana program for ‘illegally’ testing an addiction treatment on inmates

By Ed Silverman

Pharmalot

Pharmalittle: How Purdue planted its ‘anti-story’; how much does that ‘free’ flu shot cost?

By Elizabeth Cooney

Pharmalot

Pharmalittle: VCs warn Congress on drug-pricing bill; drugs look better than surgery or stents

By Elizabeth Cooney

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Senators propose a new agency to control drug costs; FDA panel backs Amarin fish-oil pill

By Ed Silverman

Pharmalot

A drug maker courted controversy when it shut out a family-run rival. Now some patients say the medicine isn’t working

By Ed Silverman

Pharmalot

FDA slams Dollar Tree for purchasing drugs from suppliers with checkered safety records

By Ed Silverman

Pharmalot

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill

By Ed Silverman

Pharmalot

Pharmalittle: WHO to advance generic insulins; Trump wants more aggressive foreign pricing index

By Ed Silverman

Pharma

After backlash, Teva will resume supplies of a critical children’s cancer medicine

By Ed Silverman

Pharmalot

Pharmalittle: Most think Trump isn’t doing enough to lower drug costs; a prolonged shortage of heparin is possible

By Ed Silverman

Pharmalot

More Americans can’t afford prescriptions and most think Trump isn’t doing enough to help

By Ed Silverman

Pharmalot

Pharmalittle: Biotechs worry about Democrats’ drug pricing bill; PhRMA criticizes four countries over policies

By Ed Silverman

Pharma

How much? Pharma copay cards are increasing costs for private Canadian insurers

By Ed Silverman

Pharma

Pharmalittle: Can Congress really pass a drug pricing bill this year? Roche closes in on SMA market

By Ed Silverman

Pharma

FDA admits it goofed when granting orphan status to an opioid addiction treatment

By Ed Silverman

Pharmalot

Former Biogen sales rep, who says she was fired for complaining about off-label marketing, is awarded $6 million

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: New York judge sets next opioid trial; FDA and DEA urged to reschedule an opioid

By Ed Silverman

Pharmalot

Italy is urged not to replace a public health official who pushed for drug pricing transparency

By Ed Silverman

Pharmalot

Another former Sun Pharma sales rep claims she was fired for complaining about off-label marketing

By Ed Silverman

Merck is probed by Spain’s antitrust regulator for allegedly delaying competition for a contraceptive

Generic trade group sues California for an ‘unconstitutional’ law banning pay-to-delay deals

Pharmalittle: Novartis to pay $9.7 billion for The Medicines Co.; Trump bashes Pelosi drug pricing bill

Up and down the ladder: The latest comings and goings

Pharmalittle: Bayer offered funding to influence foreign press group; a key Sanofi exec leaves as changes loom

Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

Pharmalittle: Trump and senators push for drug prices in TV ads; Sanofi looks to spin off consumer business

Pharmalittle: Purdue affiliate in China pushes misleading opioid claims; more generics are approved but not yet available

FDA is urged to probe a Louisiana program for ‘illegally’ testing an addiction treatment on inmates

Pharmalittle: How Purdue planted its ‘anti-story’; how much does that ‘free’ flu shot cost?

Pharmalittle: VCs warn Congress on drug-pricing bill; drugs look better than surgery or stents

Up and down the ladder: The latest comings and goings

Pharmalittle: Senators propose a new agency to control drug costs; FDA panel backs Amarin fish-oil pill

A drug maker courted controversy when it shut out a family-run rival. Now some patients say the medicine isn’t working

FDA slams Dollar Tree for purchasing drugs from suppliers with checkered safety records

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill

Pharmalittle: WHO to advance generic insulins; Trump wants more aggressive foreign pricing index

After backlash, Teva will resume supplies of a critical children’s cancer medicine

Pharmalittle: Most think Trump isn’t doing enough to lower drug costs; a prolonged shortage of heparin is possible

More Americans can’t afford prescriptions and most think Trump isn’t doing enough to help

Pharmalittle: Biotechs worry about Democrats’ drug pricing bill; PhRMA criticizes four countries over policies

How much? Pharma copay cards are increasing costs for private Canadian insurers

Pharmalittle: Can Congress really pass a drug pricing bill this year? Roche closes in on SMA market

FDA admits it goofed when granting orphan status to an opioid addiction treatment

Former Biogen sales rep, who says she was fired for complaining about off-label marketing, is awarded $6 million

Up and down the ladder: The latest comings and goings

Pharmalittle: New York judge sets next opioid trial; FDA and DEA urged to reschedule an opioid

Italy is urged not to replace a public health official who pushed for drug pricing transparency

Another former Sun Pharma sales rep claims she was fired for complaining about off-label marketing